Po-Chi Hsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Po-Chi Hsu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Chien-Chih Yeh
Department of Medical Laboratory, Taoyuan Armed Forces General Hospital, Longtan, Taoyuan 325208, Taiwan
1 shared publication - Chih-Pin Chuu
Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli 350401, Taiwan
1 shared publication - Hao-Ai Shui
Graduate Institute of Medical Sciences, College of Medicine, National Defense Medical University, Taipei 114202, Taiwan
1 shared publication - Li-Jane Shih
Taoyuan Armed Forces General Hospital; Department of Medical Laboratory, Taoyuan Armed Forces General Hospital, Longtan, Taoyuan 325, Taiwan; Graduate Institute of Medical Science, National Defense Medical Center, Taipei 114, Taiwan, Taiwan
1 shared publication - Yueh-Chung Chen
Division of Cardiology, Department of Internal Medicine, Taipei City Hospital, Renai Branch, Taipei 106243, Taiwan
1 shared publication - Yung-Hsi Kao
Department of Life Sciences, National Central University, Taoyuan, Taiwan
1 shared publication
Latest Publications
- Open Access
- 14 February 2024
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (2) , 1516-1529
Epigallocatechin-3-gallate Synergistically Enhanced Arecoline-Induced Cytotoxicity by Redirecting Cycle Arrest to Apoptosis
Carcinogens, such as arecoline, play a crucial role in cancer progression and continuous gene mutations by generating reactive oxygen species (ROS). Antioxidants can reduce ROS levels and potentially prevent cancer progression but may paradoxically enhance the survival of cancer cells. This study investigated whether epigallocatechin-3-gallate (EGCG), an antioxidant from green tea, could resolve this paradox. Prostate cancer cells (PC-3 cell line) were cultured and treated with arecoline combined with NAC (N-acetylcysteine) or EGCG; the combined effects on intracellular ROS levels and cell viability were examined using the MTT and DCFDA assays, respectively. In addition, apoptosis, cell cycle, and protein expression were investigated using flow cytometry and western blot analysis. Our results showed that EGCG, similar to NAC (N-acetylcysteine), reduced the intracellular ROS levels, which were elevated by arecoline. Moreover, EGCG not only caused cell cycle arrest but also facilitated cell apoptosis in arecoline-treated cells in a synergistic manner. These were evidenced by elevated levels of cyclin B1 and p27, and increased fragmentation of procaspase-3, PARP, and DNA. Our findings highlight the potential use of EGCG for cancer prevention and therapy.
- 14 February 2024
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (2) , 1516-1529
Open AccessEpigallocatechin-3-gallate Synergistically Enhanced Arecoline-Induced Cytotoxicity by Redirecting Cycle Arrest to Apoptosis
Carcinogens, such as arecoline, play a crucial role in cancer progression and continuous gene mutations by generating reactive oxygen species (ROS). Antioxidants can reduce ROS levels and potentially prevent cancer progression but may paradoxically enhance the survival of cancer cells. This study investigated whether epigallocatechin-3-gallate (EGCG), an antioxidant from green tea, could resolve this paradox. Prostate cancer cells (PC-3 cell line) were cultured and treated with arecoline combined with NAC (N-acetylcysteine) or EGCG; the combined effects on intracellular ROS levels and cell viability were examined using the MTT and DCFDA assays, respectively. In addition, apoptosis, cell cycle, and protein expression were investigated using flow cytometry and western blot analysis. Our results showed that EGCG, similar to NAC (N-acetylcysteine), reduced the intracellular ROS levels, which were elevated by arecoline. Moreover, EGCG not only caused cell cycle arrest but also facilitated cell apoptosis in arecoline-treated cells in a synergistic manner. These were evidenced by elevated levels of cyclin B1 and p27, and increased fragmentation of procaspase-3, PARP, and DNA. Our findings highlight the potential use of EGCG for cancer prevention and therapy.